Sun Pharma (India) plant was banned by the FDA for manufacturing issues March 13, 2014 | By Eric Palmer in FiercePharma A Sun Pharma plant has joined the growing ranks of Indian operations banned by the FDA for manufacturing issues. Unlike Ranbaxy Laboratories and Wockhardt, two other Indian generics players that have recently felt the […]
FiercePharma, December 11, 2013 | By Tracy Staton Gilead Sciences ($GILD) can take the sort of pricing protest that greeted its breakthrough hepatitis C treatment Sovaldi this week–the kind from access-to-medicine advocates. But when payers balk, that’s a different story. A horror story, even, that could frighten drugmakers long accustomed to pricing freedom in the […]